Lantus

Insulin glargine, the active ingredient in Lantus, is a long‑acting insulin presented as an injection solution for subcutaneous use. It provides basal insulin coverage to help control blood glucose levels in adults and children with type 1 or type 2 diabetes mellitus.

GNH USA supplies Lantus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance, and reliable cold‑chain logistics for this biologic product.

Lantus (insulin glargine) is a long‑acting insulin used to manage basal glucose control in diabetes.

Type 1 diabetes mellitus: provides basal insulin to maintain fasting glucose levels. Type 2 diabetes mellitus: supplies steady insulin to improve overall glycemic control when oral agents are insufficient.

Lantus may cause a range of adverse reactions.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if dose is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with improved glycemic control. - Edema: mild fluid retention in extremities. - Headache: occasional mild to moderate headache. - Lipodystrophy: localized changes in fat tissue at injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare but potentially life‑threatening allergy. - Insulin allergy: systemic rash, urticaria, or angioedema. - Serum insulin antibodies: may alter insulin action. - Acute metabolic acidosis: rare metabolic disturbance.

When using Lantus, consider the following precautions.

Dose adjustment: individualize based on regular blood glucose monitoring. Hypoglycemia risk: educate patients to recognize and treat low glucose promptly. Renal impairment: monitor kidney function and adjust dose if needed. Pregnancy and lactation: use only if benefits outweigh potential risks. Alcohol consumption: may potentiate hypoglycemia, advise moderation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lantus can interact with several medicines.

Major Interactions (Avoid): - Concurrent rapid‑acting insulin: increased risk of severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - Sulfonylureas or meglitinides: additive glucose‑lowering effect, risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may raise blood glucose, requiring dose adjustment. - Thiazide diuretics: can increase glucose levels. - ACE inhibitors: may enhance insulin sensitivity, monitor glucose.